Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study

Ida Schregel; Guilherme P. Ramos; Stephanie Ioannou; Emma Culver; Martti Färkkilä; Christoph Schramm; International PSC Study Group

doi:https://doi.org/10.1016/j.cgh.2023.01.014

Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study

Ida Schregel, Guilherme P. Ramos, Stephanie Ioannou, Emma Culver, Martti Färkkilä, Christoph Schramm, International PSC Study Group

Gastroenterology and Hepatology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	3448-3450.e3
Journal	Clinical Gastroenterology and Hepatology
Volume	21
Issue number	13
DOIs	https://doi.org/10.1016/j.cgh.2023.01.014
Publication status	Published - 1 Dec 2023

Access to Document

https://doi.org/10.1016/j.cgh.2023.01.014

Cite this

@article{422164cbaa534b30ba91872736d7ea60,

title = "Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study",

author = "Ida Schregel and Ramos, {Guilherme P.} and Stephanie Ioannou and Emma Culver and Martti F{\"a}rkkil{\"a} and Christoph Schramm and {International PSC Study Group} and John Eaton and Cynthia Levy and Olivier Chazouilleres and Tobias M{\"u}ller and Jeremy Nayagam and Deepak Joshi and Ehud Zigmond and Oren Shibolet and Drenth, {Joost P. H.} and Frank Hoentjen and Anja Geerts and Weism{\"u}ller, {Tobias J.} and Taotao Zhou",

note = "Funding Information: Funding The study was supported by the Helmut and Hannelore Greve Foundation , the YAEL Foundation , the German Research Foundation ( KFO306 , SCHR 781/3-2 ), and the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) Oxford. Funding Information: Conflicts of interest These authors disclose the following: Ehud Zigmond received consultant fees from BiomX and lecture fees from Intercept, MSD, and Neopharm; and was or is involved in clinical trials for Cymabay, Gilead, Intercept, Chemomab, Mirum, and Genkyotex. Joost Drenth declares that The Radboudumc, on behalf of Joost Drenth, received honoraria or research grants from Gilead and Abbvie. Frank Hoentjen has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, TEVA, Sandoz, and Dr Falk; received funding (grants/honoraria) from Takeda, Janssen-Cilag, and Abbvie; and received consulting fees from Celgene. Christoph Schramm received a research grant from Galapagos, not related to this work. The remaining authors disclose no conflicts.",

year = "2023",

month = dec,

day = "1",

doi = "https://doi.org/10.1016/j.cgh.2023.01.014",

language = "English",

volume = "21",

pages = "3448--3450.e3",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "13",

}

TY - JOUR

T1 - Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis

T2 - A Multicenter, Retrospective Study

AU - Schregel, Ida

AU - Ramos, Guilherme P.

AU - Ioannou, Stephanie

AU - Culver, Emma

AU - Färkkilä, Martti

AU - Schramm, Christoph

AU - International PSC Study Group

AU - Eaton, John

AU - Levy, Cynthia

AU - Chazouilleres, Olivier

AU - Müller, Tobias

AU - Nayagam, Jeremy

AU - Joshi, Deepak

AU - Zigmond, Ehud

AU - Shibolet, Oren

AU - Drenth, Joost P. H.

AU - Hoentjen, Frank

AU - Geerts, Anja

AU - Weismüller, Tobias J.

AU - Zhou, Taotao

N1 - Funding Information: Funding The study was supported by the Helmut and Hannelore Greve Foundation , the YAEL Foundation , the German Research Foundation ( KFO306 , SCHR 781/3-2 ), and the National Institute of Health Research (NIHR) Biomedical Research Centre (BRC) Oxford. Funding Information: Conflicts of interest These authors disclose the following: Ehud Zigmond received consultant fees from BiomX and lecture fees from Intercept, MSD, and Neopharm; and was or is involved in clinical trials for Cymabay, Gilead, Intercept, Chemomab, Mirum, and Genkyotex. Joost Drenth declares that The Radboudumc, on behalf of Joost Drenth, received honoraria or research grants from Gilead and Abbvie. Frank Hoentjen has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, TEVA, Sandoz, and Dr Falk; received funding (grants/honoraria) from Takeda, Janssen-Cilag, and Abbvie; and received consulting fees from Celgene. Christoph Schramm received a research grant from Galapagos, not related to this work. The remaining authors disclose no conflicts.

PY - 2023/12/1

Y1 - 2023/12/1

UR - http://www.scopus.com/inward/record.url?scp=85152639302&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.cgh.2023.01.014

DO - https://doi.org/10.1016/j.cgh.2023.01.014

M3 - Article

C2 - 36731589

SN - 1542-3565

VL - 21

SP - 3448-3450.e3

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 13

ER -

Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study

Access to Document

Other files and links

Cite this